Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma
详细信息 查看全文
- 作者：Robert H. I. Andtbacka ; Sanjiv S. Agarwala ; David W. Ollila ; Sigrun Hallmeyer ; Mohammed Milhem ; Thomas Amatruda ; John J. Nemunaitis ; Kevin J. Harrington ; Lisa Chen ; Mark Shilkrut ; Merrick Ross and Howard L. Kaufman
- 刊名：Head & Neck
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：38
- 期：12
- 页码：1752-1758
- 全文大小：482K
- ISSN：1097-0347
文摘
Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic virus talimogene laherparepvec improved durable response rate (DRR; continuous response ≥6 months) compared with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF).